Clinical Trials

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05923190 2026-03-19

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

60 enrolled

Carcinoma, Transitional Cell

NCT07090499 2026-03-19

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

GastrointestinalGenitourinaryHead & NeckThoracic

310 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Pancreatic Neoplasms

NCT07218380 2026-03-19

FORAGER-2

Phase 3 Recruiting

450 enrolled

Phase 1 Not yet recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT07484022 2026-03-19

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

37 enrolled

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT02834013 2026-03-18

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

818 enrolled

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03047213 2026-03-18

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

17 enrolled 11 charts

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03854474 2026-03-18

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

30 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03866382 2026-03-18

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

314 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT04514484 2026-03-18

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

8 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04963153 2026-03-18

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

24 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT06439836 2026-03-18

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

27 enrolled

Carcinoma, Transitional Cell

NCT06524544 2026-03-18

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

320 enrolled

Carcinoma, Transitional Cell

NCT04977453 2026-03-17

Keynote B59

317 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT06161532 2026-03-17

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

60 enrolled

Carcinoma, Transitional Cell

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Phase 2 Not yet recruiting

Carcinoma, Transitional Cell

NCT07322263 2026-03-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

174 enrolled

Phase 1/2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT05562830 2026-03-16

MK-3475-04A

48 enrolled

Carcinoma, Transitional Cell

NCT07287995 2026-03-16

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

BreastGenitourinaryThoracic

428 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT04004442 2026-03-13

COAXIN

19 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05176483 2026-03-12

STELLAR-002

GastrointestinalGenitourinaryHead & NeckThoracic

1,314 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07416123 2026-03-12

A Study of GEN1106 in Participants With Solid Tumors

103 enrolled

Phase 2 Not yet recruiting

Carcinoma, Transitional Cell

NCT07460245 2026-03-10

AVESEC

144 enrolled

Carcinoma, Transitional Cell

NCT01616875 2026-03-06

Bristol Bladder Trial

Phase 2 Completed

28 enrolled 21 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06443944 2026-03-06

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Available

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT06862219 2026-03-06

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Phase 4 Recruiting

100 enrolled

Carcinoma, Transitional Cell

NCT07129993 2026-03-05

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2/3 Recruiting

630 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07452432 2026-03-05

Korean Prospective Upper Tract Urothelial Carcinoma Cohort

Recruiting

300 enrolled

Carcinoma, Transitional Cell

NCT05321316 2026-03-04

Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma

Phase NA Recruiting

20 enrolled

Carcinoma, Transitional Cell

NCT05335941 2026-03-04

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

10 enrolled

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT07393542 2026-03-03

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

Phase 3 Recruiting

462 enrolled

Carcinoma, Transitional Cell

NCT06040762 2026-03-02

A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial

Phase NA Recruiting

128 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT07441499 2026-03-02

Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

Recruiting

300 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Carcinoma, Transitional Cell, Neoplasms

NCT07439120 2026-02-27

Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors

10 enrolled

Carcinoma, Transitional Cell

NCT04895709 2026-02-25

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

949 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06171789 2026-02-25

PRO1107 in Patients With Advanced Solid Tumors

Phase 1/2 Terminated

33 enrolled

BreastGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06695845 2026-02-25

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

200 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06412848 2026-02-24

JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study

Active not recruiting

360 enrolled

Carcinoma, Transitional Cell

NCT06657157 2026-02-24

P-EVOLUTION

Recruiting

80 enrolled

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT03252938 2026-02-19

INSIGHT

83 enrolled

GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT05239624 2026-02-19

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

23 enrolled

Carcinoma, Transitional Cell

NCT07221942 2026-02-19

IMPROEV

97 enrolled

Carcinoma, Transitional Cell

NCT07334119 2026-02-19

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

60 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07421700 2026-02-19

A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Phase 1/2 Not yet recruiting

132 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

12 enrolled

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06483334 2026-02-18

MK-3475-04C

38 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT05581004 2026-02-17

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

450 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT05868265 2026-02-17

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

24 enrolled